Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus fumigatus characterized by histologic and physiologic features of asthma along with eosinophilic inflammation, bronchiectasis, mucoid impaction, and bronchocentric granulomatosis.1 Here, we report the case of a 58-year-old woman with severe, treatment refractory ABPA successfully treated with combination therapy of omalizumab (an anti-IgE mAb) and mepolizumab (an anti–IL-5 mAb).